A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.
|ClinicalTrials.gov Identifier: NCT00420472|
Recruitment Status : Terminated
First Posted : January 11, 2007
Last Update Posted : November 20, 2007
|Condition or disease||Intervention/treatment||Phase|
|Kidney Transplantation||Drug: mycophenolate mofetil [CellCept]||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept|
|Study Start Date :||March 2007|
- Gastrointestinal Quality of Life index, and Gastrointestinal Symptom Rating Scale, at 3 months.
- Efficacy: Mean dose increase of CellCept. Pharmacokinetics: Comparison of pharmacokinetic parameters under EC-MPS and CellCept therapy. Safety: AEs; acute rejection episodes.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00420472
|Berlin, Germany, 10117|
|Berlin, Germany, 13353|
|Dresden, Germany, 01307|
|Essen, Germany, 45122|
|Hannover, Germany, 30625|
|Köln, Germany, 51109|
|Münster, Germany, 48149|
|Study Director:||Clinical Trials||Hoffmann-La Roche|